title: Usefulness of Reticulocyte Hemoglobin Equivalent in Management of Regular Hemodialysis Patients with Iron Deficiency Anemia.
abstract: BACKGROUND
  Reticulocyte hemoglobin equivalent (RET-He) is a new parameter for evaluating iron status. This study aims to assess diagnostic value and investigate RET-He as early predictor of response to intravenous iron supplementation.
  
  
  METHODS
  Seventy-two regular hemodialysis patients at Adam Malik Hospital were studied from April to May 2011. RET-He was compared with conventional iron parameters for identification of iron deficiency. Fifteen patients with iron deficiency anemia were selected to receive 100 mg iron sucrose intravenous during every dialysis session (2x/weeks) for 4 weeks.
  
  
  RESULTS
  Receiver operating characteristic (ROC) curve for RET-He revealed the value of area under the curve was 0.818 (p < 0.0001). Using cutoff level 31.65 pg, RET-He showed 81.5% sensitivity and 61.6% specificity. Serum ferritin (r = 0.499, p < 0.0001) and transferrin saturation/ TSAT (r = 0.592, p < 0.0001) were correlated to RET-He. Significant improvement in hemoglobin, hematocrit and RET-He were found after intervention (p = 0.023, p = 0.049 and p = 0.019, respectively).
  
  
  CONCLUSIONS
  RET-He is a useful marker of iron deficiency and early predictor of response to intravenous iron supplementation in regular hemodialysis patients.
authors.forename: Naomi Niari
authors.initials: NN
authors.lastname: Dalimunthe
authors.forename: Abdurrahim Rasyid
authors.initials: AR
authors.lastname: Lubis
mesh_terms: D000328:Adult; D018798:Anemia, Iron-Deficiency / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism; D015415:Biomarkers / Q000378:metabolism; D015331:Cohort Studies; D005260:Female; D005290:Ferric Compounds / Q000627:therapeutic use; D000077605:Ferric Oxide, Saccharated; D005293:Ferritins / Q000378:metabolism; D005937:Glucaric Acid / Q000627:therapeutic use; D006397:Hematinics / Q000627:therapeutic use; D006454:Hemoglobins / Q000378:metabolism*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012372:ROC Curve; D006435:Renal Dialysis; D012156:Reticulocytes / Q000378:metabolism*; D014168:Transferrin / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D005290:Ferric Compounds; D006397:Hematinics; D006454:Hemoglobins; D014168:Transferrin; D005293:Ferritins; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid